Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 309Carcinoma, Non-Small-Cell Lung 281Prostatic Neoplasms 160Colorectal Neoplasms 155Carcinoma, Hepatocellular 144Neoplasms 134Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 108Multiple Myeloma 103Triple Negative Breast Neoplasms 102Recurrence 99Pancreatic Neoplasms 93Stomach Neoplasms 92Ovarian Neoplasms 87Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Rectal Neoplasms 62Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 57Myelodysplastic Syndromes 55Lymphoma 55Esophageal Squamous Cell Carcinoma 54

Interventions

Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Metastatic Pancreatic Adenocarcinoma × Clear all
NCT06576115 2025-11-05

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡